The FDA has given compounding pharmacies and facilities a deadline of April 22, 2025, or May 22, 2025 (depending on the type of compounding pharmacy or facility) to stop offering compounded semaglutide
Based on announcements in early 2026, the FDA and HHS signaled reclassifying a group of peptides, including BPC-157, TB-500, and injectable GHK-Cu, toward Category 1, which makes them eligible for use by licensed compounding pharmacies preparing individualized medications under a prescription
Aches and stiffness that sideline the activities you love
For reconstituting GHK-Cu, your setup is straightforward, but every single item is non-negotiable
10.1124/mol.114.094128 49
Journal of molecular medicine (Berlin, Germany), 95(3), 323333